AKL-T01
Sponsors
Akili Interactive Labs, Inc., Weill Medical College of Cornell University, Vanderbilt University Medical Center
Conditions
Attention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderCognitive DysfunctionCognitive ImpairmentCovid19DepressionExecutive DysfunctionStroke
Phase 2
Unknown Phase
Software Treatment for Actively Reducing Severity of ADHD
CompletedNCT02674633
Start: 2016-05-31End: 2017-08-31Updated: 2020-08-14
Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant
CompletedNCT03649074
Start: 2018-12-28End: 2019-09-23Updated: 2023-08-09
Electroencephalogram (EEG) Study of Inattention Following Treatment With AKL-T01
CompletedNCT03844269
Start: 2019-05-10End: 2020-02-01Updated: 2023-11-14
Software Treatment for Actively Reducing Severity of ADHD in Adolescents (STARS-ADHD-Adolescents)
CompletedNCT04897074
Start: 2021-06-29End: 2022-09-01Updated: 2023-08-14
Cognitive Training in Survivors of Covid-19: A Randomized Trial
CompletedNCT04956887
Start: 2021-08-03End: 2024-12-31Updated: 2025-04-30